Press

Novel Akadeum microbubble technology can be the answer to improved quality and reduced costs across multiple fields of testing.

October 30, 2019, Ann Arbor, MI – Akadeum Life Sciences, Inc., an Ann Arbor-based biotechnology company, announced today that it has entered into a collaboration with Agilent Technologies, Inc. to work toward a new method of isolating target molecules for detection. Akadeum aims to disrupt the status quo in isolation technology with their buoyant microbubbles. Notably, Akadeum is the first company to commercialize buoyancy-based cell isolation with their growing portfolio of human and mouse cell enrichment kits for immunology researchers. In addition, the same technology can be leveraged to improve isolation workflows and capabilities for target molecules such as DNA, protein, microbes, and others; which, Akadeum is developing through strategic partnerships.

“Sample preparation is a critical, yet often undervalued, step in most analytical assays. Often, the task of sample preparation employs decades old technology that is manual, time-consuming, and resource-intensive,” said Brandon McNaughton, CEO of Akadeum Life Sciences. “Akadeum was founded to bring simple and superior isolation solutions to a variety of industries through our buoyancy-based microbubble technology and we are excited to be starting work with Agilent to explore new applications.”

Agilent, an early investor in Akadeum, has engaged in this collaboration with the

Fusion Coolant Systems, manufacturer of an advanced coolant and lubrication system called “Pure-Cut™,” has seen some of the largest automotive, aerospace and medical device manufacturers around the world come through their doors. The global emphasis on sustainable development has played a dynamic role in Fusion’s recent success, with companies looking for a cleaner, safer and more efficient alternative to traditional cutting fluids. With multiple customer visits scheduled every week, Fusion has expanded their facility and capabilities to set them up for long term success.

Expanded Customer Center

With a rapid increase in customer demand, Fusion has responded by expanding their Customer Center in Canton, Michigan. “We have added more machining capacity, doubled the size of our facility and expanded our research efforts into different materials and operations” said Brian Ahlborn, President and CEO of Fusion. “We also installed a larger recycled CO2 tank to support the additional machine tools. It’s large enough to provide for future expansion as well” The additional infrastructure will support both customer test applications and internal research development.

In the last year, Fusion has seen their Customer Center grow to three machine tools, and a fully integrated, advanced CO2 unit that can handle up to 10 Pure-Cut™ boxes. “The CO2 infrastructure we installed at our own facility is very similar to what our customers install at their sites” said Scott Jones, Dire

ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204

ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study

ANN ARBOR, MI – October 23, 2019

ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been treated in the company’s First-in-Human trial with its lead drug candidate ONL1204. The study is being conducted in Australia at leading clinical research centers in Sydney and Melbourne. The study will assess four different doses of ONL1204 and is designed to demonstrate safety and tolerability of the investigational drug in patients with a macula-off rhegmatogenous retinal detachment (RRD).

“This is a transformational step for our company with the announcement of our first patient being treated with ONL1204,” commented David Esposito, CEO of ONL Therapeutics. “I want to thank our dedicated team, our investors, and retinal surgeons around the world who have been seeking a therapeutic intervention to support improving the outcome of the current standard of care surgery for macula-off RRD. We look forward to working with retinal specialists to utilize our Fas inhibition platform to protect the vision of patients with retinal disease.”

ONL1204 has been granted orphan drug designation for the treatment of retinal detachment by the United States Food and Drug Administration (FDA). The company is emba

This press release is submitted and shown here in its original form, unedited by Furniture Today.

After Generating Millions in Incremental Revenue for its Furniture Clients, Expands into Store and Outbound Channels

This press release is submitted and shown here in its original form, unedited by Furniture Today.

After Generating Millions in Incremental Revenue for its Furniture Clients, Expands into Store and Outbound Channels

ANN ARBOR, MI – October 16, 2019 – Shoptelligence announced today that its AI-Powered platform has consistently proven its ability to increase revenue per buyer by over 30% and has delivered millions in incremental revenue for its Top 100 furniture retail clients. This milestone is an important one for Shoptelligence as the platform officially launched at the October 2018 High Point Furniture Market and is now expanding its offerings to deliver similar results in-store and via outbound marketing.

The SaaS platform provides the assistance of an interior designer at every customer touchpoint, helping the shopper find the right item then reasoning like a designer to curate interactive cross-category room assortments specific to that shopper’s style and the room they are furnishing. Shoptelligence’s unique ability to combine inspiration and assistive selling has increased its clients’ online revenue by 2.7%, with purchases that result from the interactions accounting for 13% of total client online revenue. In an era where retail traffic is down, retailers must g

ANN ARBOR, MICH. (PRWEB) OCTOBER 16, 2019

Ripple Science, a SaaS company accelerating clinical research, will attend the SaaS CXO summit in San Antonio, Texas. The SaaS CXO Summit is an opportunity for executives, venture capitalists, corporates, and sponsors to network, matchup and share best practices.

Ripple Science CEO Peter Falzon explains, “Attending the largest gathering of SaaS ecosystem participants in the Midwest further expands the opportunity for Ripple to achieve fundraising goals in less than the anticipated timeframe.”

Ripple Science is currently seeking a lead investor for a two-million-dollar seed round. The CXO Summit begins on October 22.

About Ripple Science:
Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up.
Ripple Science’s flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.
To learn more, please visit: https://www.ripplescience.com

Orbion appoints Greg Orndorff as Vice President of Business Development

HOUGHTON, Mich., Oct. 16, 2019 (GLOBE NEWSWIRE) — Orbion Space Technology, developer of next-generation smallsat propulsion systems, today announced the appointment of Greg Orndorff, Vice President of Business Development.

Greg is an aerospace industry veteran with over 30 years of experience across various leadership roles in the public, private, and not-for-profit sectors. Most recently, Greg was Vice President, Government Systems at Vector Launch—responsible for developing a New Space commercial launch initiative for the United States Government. Prior to Vector Launch, Greg held executive and senior management roles at SGT, Inc., the Johns Hopkins University Applied Physics Laboratory (Space department), Northrop Grumman, and Orbital Sciences Corporation. Greg is a former United States Air Force Officer where he performed tours in operations and acquisition of space systems.

“Until Orbion instantiated electric propulsion for the New Space architectures, small satellite developers were limited on system choices, had to wait forever, and paid an arm and leg for them,” said Greg Orndorff, Vice President of Business Development, Orbion Space Technology. “I am excited to join the Orbion team to help deliver its vision of cheaper, faster, and better access to space for the next generation of space

It feels like the cure for every problem these days is mediation. Feeling anxious? Meditate for 20 minutes a day. Need help falling asleep? Again, meditate. Feeling lost and disconnected? You get the point. But whether you’re new to meditation or just looking to feel more peaceful in your everyday life, a cramped and chaotic apartment can seem like an enormous roadblock. Sure, it’s ideal to retreat to an empty, sun-drenched room to do your morning meditation or a lush backyard where you can surround yourself in nature every day. But we’re happy to report that you can still curate a mindful meditation space even in the most cramped, eclectic, and chaotic of dwellings. Here are some hacks to create a conscious corner for you and your practice.

DETROIT—(BUSINESS WIRE)—Autobooks is a small business payment and accounting platform integrated within a financial institution’s digital banking experience. Today, the company announced that Derik Sutton, vice president of product & experience at Autobooks, has been elected to serve on the Association for Financial Technology’s (AFT) Web Board. Sutton previously served as vice-chair of the organization’s Digital Experience Group (DEG).

.@Autobooks_ announced today that @deriksutton was elected to serve on @AFTWeb’s Board.

Founded in 1972, AFT is the premier resource for networking and professional development for companies and executives serving the United States financial institutions, including banks, credit unions, lenders and payment companies. The association represents members within every area of technology, data or services needed to help financial institutions succeed in today’s dynamic marketplace. Leading financial technology companies from around the world meet twice a year to discuss industry-wide issues and collaborate on solutions.

Brian Otte, president of Association for Financial Technology and director of sales for ProfitStars ®, a division of Jack Henry & Associates, In

Genomenon® announced today at the American Society of Human Genetics Annual Meeting (ASHG) a partnership with SOPHiA GENETICS that includes incorporating the Mastermind® Genomic Search Engine into the SOPHiA Platform and the Alamut Suite. The partnership puts the most up-to-date genomic research at the fingertips of clinical researchers performing genomic analysis worldwide.

The SOPHiA Platform is the technology of choice for streamlined Data-Driven Medicine, including clinical-grade genomic analysis, interpretation, and reporting. SOPHiA has been adopted by 1,000 healthcare institutions to date and analyzed more than 420,000 genomic profiles - 16,000 new profiles processed each month. The Alamut Suite powered by SOPHiA is a decision-support software designed to explore and investigate variations of the human genome. Alamut helps clinical researchers in the complex tasks of genomic variants annotations, filtration, and exploration.

With the addition of Mastermind, users of both technologies will be able to quickly access the genomic evidence associated with human variants, shortening the search time required to interpret a variant and assess its pathogenicity.

This partnership will allow SOPHiA’s users to see a wider picture of the detected

DETROIT – Twenty-four semi-finalists were announced Monday for the 10th annual Accelerate Michigan Innovation Competition where the top prize is $350,000.

The semi-finalists were drawn from nearly 300 registered companies. These semi-finalists will have the opportunity to meet-on-one with investors to discuss their business proposals. Judges will then select six finalists to present live at a seated dinner to more than 400 investors, entrepreneurs and community leaders on November 13 at the State Savings Bank in Detroit. 

“The selected semi-finalists showcase the momentum of Michigan’s entrepreneurial ecosystem over the past decade,” said Martin Dober, senior vice president and managing director of ID Ventures. “Each year, we see more incredible talent and companies that are transforming the way legacy industries operate. We are proud to support the development of these Michigan-based companies that will continue to drive our economy and shine a national spotlight on the innovation happening in the state.”

 The pitch competition supports Michigan’s entrepreneurial ecosystem by offering entrepreneurs the opportunity to showcase their companies to investors while building connections with entrepreneurs, business acceleration resources and experts in their sector during carefully curated individual meetings. Since its launch in 2010, Accelerate Michigan Innovation Competition semi-finalists have created over 1,300 jobs and attracted more than $900 million in additional investment. Top awards include a

Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia

ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the initiation of the company’s First-in-Human trial with its lead drug candidate ONL1204. The study is being conducted in Australia at leading clinical research centers in Sydney and Melbourne. The study will assess four different doses of ONL1204 and is designed to demonstrate safety and tolerability of the investigational drug in patients with a macula-off rhegmatogenous retinal detachment (RRD).

“Today marks a major milestone in the history of ONL Therapeutics as we transition into a clinical-stage pharmaceutical company,” commented David Zacks, MD, PhD, Founder and Chief Scientific Officer of ONL Therapeutics. “We see great potential in the role of Fas inhibition to protect the vision of patients with retinal cell disease, and our first-in-human study with ONL1204 helps build the foundation to make a meaningful difference in the lives of patients.”

ONL1204 has been granted orphan drug designation for the treatment of retinal detachment by the United States Food and Drug Administration (FDA). The Company is embarking on a Series B round of financing to continue funding its clinical development plans for ONL1204 and expand the development

SALINE, MI — What started as a physician’s idea to help protect patients’ teeth has grown into a decade-old business that supplies oral safety equipment to sports teams all over the country.

Saline-based Akervall Technologies marked its 10-year anniversary last month, celebrating the successful development of an idea to create a more manageable mouthguard.

Read the full article in the MLive: https://www.mlive.com/news/ann-arbor/2019/10/saline-maker-of-breathable-mouthguards-celebrates-10-years.html